The ARFGEF family, short for ADP-ribosylation factor guanine nucleotide exchange factors, encompasses a group of proteins that are key regulators of vesicle trafficking within cells. These proteins function primarily as guanine nucleotide exchange factors (GEFs) for ADP-ribosylation factors (ARFs), which are small GTP-binding proteins involved in vesicle formation and transport. ARFGEFs catalyze the exchange of GDP for GTP on ARFs, activating them to initiate the budding of transport vesicles from various membranes, including the Golgi apparatus and the endoplasmic reticulum. Members of the ARFGEF family, such as BIG1, BIG2 and BIG3, are particularly important in the regulation of vesicle trafficking in the secretory pathway, which is crucial for the transport of proteins and lipids throughout the cell. Dysregulation of ARFGEF function has been implicated in several diseases, including neurological disorders and cancer, due to their role in intracellular transport and signaling.
Targeting ARFGEFs (ADP-ribosylation factor guanine nucleotide exchange factors) with small molecules allows for a direct investigation into the molecular mechanisms of vesicle trafficking and membrane dynamics in cells. By inhibiting or disrupting ARFGEF activity, these small molecules can help delineate the specific roles of ARFGEFs in processes like protein and lipid transport, Golgi apparatus function, and cell signaling. This approach not only aids in understanding the fundamental aspects of cell biology but also provides insights into targeting of ARFGEFs in diseases where their dysregulation is a contributing factor, such as in certain cancers and neurological disorders.
VOIR ÉGALEMENT...
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Connu pour inhiber la fonction des ARFGEF, y compris BIG1 et BIG2, en stabilisant leur interaction avec les ARF dans leur état lié au PIB, ce qui perturbe la structure et la fonction du Golgi. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Inhibe spécifiquement ARFGEF1 (BIG1) et ARFGEF2 (BIG2), affectant le transport rétrograde du Golgi vers le RE médié par ARF. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
Bien que sa cible principale soit les cytohésines (un autre sous-groupe d'ARFGEF), il peut également affecter les ARFGEF de la famille BIG en raison de la similitude de leur mécanisme. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $87.00 $282.00 | 1 | |
En ciblant le complexe Exocyst, il affecte indirectement les processus régulés par les ARFGEF, y compris le trafic des vésicules. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Connu pour ses propriétés de perturbation de l'actine, il a un impact indirect sur le trafic des vésicules, ce qui pourrait affecter les processus régulés par l'ARFGEF. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
Un inhibiteur de Cdc42, qui affecte indirectement les voies impliquant les ARFGEF. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
Inhibe principalement l'endocytose médiée par la clathrine, mais pourrait indirectement affecter les fonctions de l'ARFGEF. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
Un inhibiteur de p97/VCP qui peut indirectement affecter la fonction des ARFGEF, en particulier dans le contexte de la dégradation associée au RE. | ||||||